- Home
- EXFY vs KOD Comparison
EXFY vs KOD Comparison
Compare EXFY & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- KOD
- Stock Information
- Founded
- EXFY 2008
- KOD 2009
- Country
- EXFY United States
- KOD United States
- Employees
- EXFY N/A
- KOD N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EXFY Technology
- KOD Health Care
- Exchange
- EXFY Nasdaq
- KOD Nasdaq
- Market Cap
- EXFY 253.2M
- KOD 259.6M
- IPO Year
- EXFY 2021
- KOD 2018
- Fundamental
- Price
- EXFY $2.21
- KOD $3.40
- Analyst Decision
- EXFY Buy
- KOD Hold
- Analyst Count
- EXFY 4
- KOD 3
- Target Price
- EXFY $4.75
- KOD $9.00
- AVG Volume (30 Days)
- EXFY 478.8K
- KOD 440.1K
- Earning Date
- EXFY 05-08-2025
- KOD 05-14-2025
- Dividend Yield
- EXFY N/A
- KOD N/A
- EPS Growth
- EXFY N/A
- KOD N/A
- EPS
- EXFY N/A
- KOD N/A
- Revenue
- EXFY $141,775,000.00
- KOD N/A
- Revenue This Year
- EXFY $7.77
- KOD N/A
- Revenue Next Year
- EXFY $5.45
- KOD N/A
- P/E Ratio
- EXFY N/A
- KOD N/A
- Revenue Growth
- EXFY N/A
- KOD N/A
- 52 Week Low
- EXFY $1.24
- KOD $1.92
- 52 Week High
- EXFY $4.13
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- EXFY 35.69
- KOD 45.30
- Support Level
- EXFY $2.22
- KOD $3.46
- Resistance Level
- EXFY $2.50
- KOD $3.81
- Average True Range (ATR)
- EXFY 0.12
- KOD 0.42
- MACD
- EXFY -0.01
- KOD -0.07
- Stochastic Oscillator
- EXFY 13.43
- KOD 34.50
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.